India · Delayed Price · Currency is INR Regulus Therapeutics Statistics
Total Valuation
NSE:JBCHEPHARM has a market cap or net worth of INR 264.56 billion. The enterprise value is 260.34 billion.
| Market Cap | 264.56B |
| Enterprise Value | 260.34B |
Important Dates
The last earnings date was Sunday, August 3, 2025.
| Earnings Date | Aug 3, 2025 |
| Ex-Dividend Date | Jul 30, 2025 |
Share Statistics
| Current Share Class | 156.32M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 81.04M |
Valuation Ratios
The trailing PE ratio is 38.61 and the forward PE ratio is 31.69.
| PE Ratio | 38.61 |
| Forward PE | 31.69 |
| PS Ratio | 6.60 |
| PB Ratio | 7.71 |
| P/TBV Ratio | 12.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 38.00 |
| EV / Sales | 6.50 |
| EV / EBITDA | 24.63 |
| EV / EBIT | 29.63 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | n/a |
| Interest Coverage | 143.68 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 16.24% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 7.56M |
| Profits Per Employee | 1.29M |
| Employee Count | 5,304 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:JBCHEPHARM has paid 2.34 billion in taxes.
| Income Tax | 2.34B |
| Effective Tax Rate | 25.46% |
Stock Price Statistics
The stock price has decreased by -12.11% in the last 52 weeks. The beta is -0.10, so NSE:JBCHEPHARM's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -12.11% |
| 50-Day Moving Average | 1,698.36 |
| 200-Day Moving Average | 1,711.19 |
| Relative Strength Index (RSI) | 48.49 |
| Average Volume (20 Days) | 441,046 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JBCHEPHARM had revenue of INR 40.08 billion and earned 6.85 billion in profits. Earnings per share was 43.15.
| Revenue | 40.08B |
| Gross Profit | 26.46B |
| Operating Income | 8.79B |
| Pretax Income | 9.19B |
| Net Income | 6.85B |
| EBITDA | 10.45B |
| EBIT | 8.79B |
| Earnings Per Share (EPS) | 43.15 |
Balance Sheet
The company has 4.50 billion in cash and 278.90 million in debt, giving a net cash position of 4.22 billion.
| Cash & Cash Equivalents | 4.50B |
| Total Debt | 278.90M |
| Net Cash | 4.22B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 34.33B |
| Book Value Per Share | 220.54 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 66.02%, with operating and profit margins of 21.92% and 17.10%.
| Gross Margin | 66.02% |
| Operating Margin | 21.92% |
| Pretax Margin | 22.94% |
| Profit Margin | 17.10% |
| EBITDA Margin | 26.08% |
| EBIT Margin | 21.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 15.50, which amounts to a dividend yield of 0.90%.
| Dividend Per Share | 15.50 |
| Dividend Yield | 0.90% |
| Dividend Growth (YoY) | 26.53% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.13% |
| Shareholder Yield | 1.04% |
| Earnings Yield | 2.59% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 18, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 18, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |